不同剂量阿托伐他汀对高脂血症患者高敏C反应蛋白及颈动脉内膜中层厚度的影响

Different Doses of Atorvastatin on Hyperlipidemia in Patients with High-Sensitivity C-Reactive Protein and Carotid Artery Intima-media Thickness

关键词:  阿托伐他汀  高脂血症  高敏C反应蛋白  血管内皮

Key words:  atorvastatin  hyperlipidemia  high-sensitivity C-reactive protein  vascular endothelial

摘要:

目的 观察强化降脂对高脂血症患者高敏C反应蛋白和颈动脉内膜中层厚度(CIMT)的影响。方法 164例高血脂症患者随机分为常规治疗组79例，强化降脂组85例，分别予阿托伐他汀10 mg·d^-1或40 mg·d^-1。于用药前及用药6个月后测定总胆固醇(TC)，低密度脂蛋白胆固醇(LDL-C)，高密度脂蛋白胆固醇(HDL-C)，甘油三酯(TG)。观察高敏Ｃ反应蛋白(hs-CRP)及CIMT的变化。结果 强化降脂组，hs-CRP由用药前(5.14±0.96)mg·L^-1，降至用药6个月时的(1.58±0.25)mg·L^-1 (P<0.05)，较常规治疗组(5.16±0.98)mg·L^-1降至(2.68±0.5)mg·L^-1有更显著的疗效。强化降脂组CIMT由用药前(1.54±0.17)mm，降至用药6个月时的(1.41±0.21)mm (P<0.05)，较常规治疗组(1.54±0.16)mm降至(1.51±0.17)mm有显著的效果。结论 强化降脂治疗能更有效地降低高敏C反应蛋白(hs-CRP)，降低CIMT。

Abstract:

OBJECTIVE To investigate the effect of intensive lipid-lowering hyperlipidemia in patients with high-sensitivity c-reactive protein and carotid artery intima-media thickness (CIMT). METHODS 164 cases of hyperlipidemia were randomly divided into conventional treatment group 79 cases, 85 cases of intensive lipid-lowering group, were to atorvastatin 10 mg·d^-1 or 40 mg·d^-1. In the former drug use and 6 months after the determination of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides (TG). Observe high sensitive C-reactive protein (hs-CRP) and CIMT. RESULTS The outcome of intensive lipid-lowering group, hs-CRP by the former administration (5.14±0.96)mg·L^-1, drug use fell to 6 months at the time of (1.58±0.25)mg·L^-1(P<0.05), than conventional treatment group (5.16±0.98)mg·L^-1 reduced (2.68±0.5)mg·L^-1 have a more significant effect. CIMT group of intensive lipid-lowering drugs by the former (1.54±0.17)mm, drug use fell to 6 months at the time of (1.41±0.21)mm (P<0.05), than the conventional treatment group (1.54±0.16)mm to (1.51±0.17)mm significant results. CONCLUSION Intensive lipid-lowering therapy method is more effective in reducing high-sensitivity C-reactive protein (hs-CRP), reducing CIMT.